retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Eli Lilly's shows promising weight loss results in trial Retatrutide vs. Tirzepatide: The Next-Gen
Description
with a GLP-1
With antiamyloid antibodies Leqembi (lecanemab) and Kisunla (donanemab) now FDAapproved for early Alzheimers, attention is turning to combination strategies that address multiple disease pathways
In this randomized clinical trial ...
Pfizer's obesity pill danuglipron has not progressed to Phase 3 trials and is not approved in the UK
